The cellular requirements for activation of herpesvirus fusion and entry remain poorly understood. Low pH triggers change in the antigenic reactivity of the prefusion form of the herpes simplex virus (HSV) fusion protein gB in virions, both in vitro and during viral entry via endocytosis (S. Dollery et al., J. Virol. 84:3759-3766, 2010). However, the mechanism and magnitude of gB conformational change are not clear. Here we show that the conformation and oligomeric state of gB with mutations in the bipartite fusion loops were similarly altered despite the fusion-inactivating mutations. Together with previous studies, this suggests that fusion loop mutants undergo conformational changes but are defective for fusion because they fail to make productive contact with the outer leaflet of the host target membrane. A direct, reversible effect of low pH on the structure of gB was detected by fluorescence spectroscopy. A soluble form of gB containing cytoplasmic tail sequences (s-gB) was triggered by mildly acidic pH to undergo changes in tryptophan fluorescence emission, hydrophobicity, antigenic conformation, and oligomeric structure and thus resembled the prefusion form of gB in the virion. In contrast, soluble gB730, for which the postfusion crystal structure is known, was only marginally affected by pH using these measures. The results underscore the importance of using a prefusion form of gB to assess the activation and extent of conformation change. Further, acidic pH had little to no effect on the conformation or hydrophobicity of gD or on gD's ability to bind nectin-1 or HVEM receptors. Our results support a model in which endosomal low pH serves as a cellular trigger of fusion by activating conformational changes in the fusion protein gB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196434PMC
http://dx.doi.org/10.1128/JVI.05291-11DOI Listing

Publication Analysis

Top Keywords

prefusion form
16
conformation oligomeric
12
oligomeric state
8
form herpes
8
herpes simplex
8
simplex virus
8
fusion
8
fusion protein
8
conformational changes
8
conformation
5

Similar Publications

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) cause human respiratory diseases and are major targets for vaccine development. In this study, we design uncleaved prefusion-closed (UFC) trimers for the fusion protein (F) of both viruses by examining mutations critical to F metastability. For RSV, we assess four previous prefusion F designs, including the first and second generations of DS-Cav1, SC-TM, and 847A.

View Article and Find Full Text PDF

Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine platform called self-amplifying RNA (saRNA) holds promise in eliciting humoral and cellular immune responses. We evaluate the immunogenicity of a lipid nanoparticle (LNP)-formulated saRNA vaccine called SMARRT.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers developed a new subunit vaccine using a stabilized mumps fusion glycoprotein (Pre-F) and a chimeric immunogen, which showed strong immune responses in mice against various mumps genotypes.
  • * The study identified specific antibodies against the Pre-F and hemagglutinin neuraminidase (HN), which could neutralize the virus effectively, suggesting these new immunogens could enhance existing vaccine-induced immunity or serve as improved vaccine options.
View Article and Find Full Text PDF
Article Synopsis
  • Initial studies showed that SARS-CoV-2 spike protein vaccines had sub-optimal effectiveness in mammals, leading researchers to explore improvements through protein engineering and adjuvants.
  • The comparison of engineered protein vaccines and protein-nanoparticle vaccines was rare, prompting experiments where mice and hamsters were vaccinated with sequence-optimized spike proteins and nanoparticles.
  • Results indicated that the immune response and protection from the virus were similar for both spike-only and spike-nanoparticle vaccines, suggesting that optimized protein subunit vaccines in trimer form can be just as effective as scaffolded versions.
View Article and Find Full Text PDF

The FDA's approval of Pfizer's new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!